STAT2 is an essential adaptor in USP18-mediated suppression of type I interferon signaling

DC ElementWertSprache
dc.contributor.authorArimoto, Kei-ichiro
dc.contributor.authorLoechte, Sara
dc.contributor.authorStoner, Samuel A.
dc.contributor.authorBurkart, Christoph
dc.contributor.authorZhang, Yue
dc.contributor.authorMiyauchi, Sayuri
dc.contributor.authorWilmes, Stephan
dc.contributor.authorFan, Jun-Bao
dc.contributor.authorHeinisch, Juergen J.
dc.contributor.authorLi, Zhi
dc.contributor.authorYan, Ming
dc.contributor.authorPellegrini, Sandra
dc.contributor.authorColland, Frederic
dc.contributor.authorPiehler, Jacob
dc.contributor.authorZhang, Dong-Er
dc.date.accessioned2021-12-23T16:23:06Z-
dc.date.available2021-12-23T16:23:06Z-
dc.date.issued2017
dc.identifier.issn15459993
dc.identifier.urihttps://osnascholar.ub.uni-osnabrueck.de/handle/unios/14419-
dc.description.abstractType I interferons (IFNs) are multifunctional cytokines that regulate immune responses and cellular functions but also can have detrimental effects on human health. A tight regulatory network therefore controls IFN signaling, which in turn may interfere with medical interventions. The JAK-STAT signaling pathway transmits the IFN extracellular signal to the nucleus, thus resulting in alterations in gene expression. STAT2 is a well-known essential and specific positive effector of type I IFN signaling. Here, we report that STAT2 is also a previously unrecognized, crucial component of the USP18-mediated negative-feedback control in both human and mouse cells. We found that STAT2 recruits USP18 to the type I IFN receptor subunit IFNAR2 via its constitutive membrane-distal STAT2-binding site. This mechanistic coupling of effector and negative-feedback functions of STAT2 may provide novel strategies for treatment of IFN-signaling-related human diseases.
dc.description.sponsorshipNIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HL091549, R01CA177305]; DFGGerman Research Foundation (DFG)European Commission [SFB 944]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA177305] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL091549] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008666] Funding Source: NIH RePORTER; We thank A. Garcia-Sastre (Icahn School of Medicine at Mount Sinai) for Stat2<SUP>-/-</SUP> MEFs, D. Cheresh (Moores UCSD Cancer Center) for MDA-MB-231, G. Stark (Cleveland Clinic) for sharing U-series cell lines, S. Fujita (Ehime University School of Medicine) for KT-1 cells, R. Xiang (The Scripps Research Institute) for WEHI-3B cells, S. Urbe (University of Liverpool) for GFP-fusion STAT2 and USP18 constructs, V. Verkhusha (Albert Einstein College of Medicine) for the mTag-BFP construct, T. Akagi (KAN Research Institute) for providing pCX4-series vectors, S. Kotenko (Rutgers New Jersey Medical School) for the pcDEF-hIFNAR2 DNA construct, D. Baker (Biogen Idec) for supplying recombinant human IFN beta and anti-human IFNAR1 antibody, the staff of Hybrigenics for their contribution, G. Hikade for technical support, and R. Kurre for advice on fluorescence microscopy. This study was supported by NIH R01HL091549 and R01CA177305 to D.-E.Z. and SFB 944 from the DFG to J.P. and J.J.H.
dc.language.isoen
dc.publisherNATURE PUBLISHING GROUP
dc.relation.ispartofNATURE STRUCTURAL & MOLECULAR BIOLOGY
dc.subjectALPHA-INTERFERON
dc.subjectBINDING
dc.subjectBiochemistry & Molecular Biology
dc.subjectBiophysics
dc.subjectCell Biology
dc.subjectGENES
dc.subjectIFN-LAMBDA
dc.subjectIMMUNE-RESPONSE
dc.subjectISG15
dc.subjectRECEPTOR DIMERIZATION
dc.subjectTRANSCRIPTION
dc.subjectUBIQUITIN-SPECIFIC PROTEASE
dc.subjectUBP43 USP18
dc.titleSTAT2 is an essential adaptor in USP18-mediated suppression of type I interferon signaling
dc.typejournal article
dc.identifier.doi10.1038/nsmb.3378
dc.identifier.isiISI:000395826000012
dc.description.volume24
dc.description.issue3
dc.description.startpage279+
dc.contributor.orcid0000-0003-4422-4914
dc.contributor.orcid0000-0001-5837-7589
dc.contributor.orcid0000-0001-5837-7589
dc.contributor.orcid0000-0002-1709-3659
dc.contributor.orcid0000-0002-4112-710X
dc.contributor.researcheridG-3801-2017
dc.contributor.researcheridQ-4790-2018
dc.contributor.researcheridY-6351-2019
dc.contributor.researcheridG-5546-2015
dc.contributor.researcheridE-7155-2012
dc.identifier.eissn15459985
dc.publisher.place75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
dcterms.isPartOf.abbreviationNat. Struct. Mol. Biol.
dcterms.oaStatusGreen Submitted, Green Accepted
crisitem.author.deptFB 05 - Biologie/Chemie-
crisitem.author.deptidfb05-
crisitem.author.orcid0000-0002-2143-2270-
crisitem.author.parentorgUniversität Osnabrück-
crisitem.author.netidPiJa938-
Zur Kurzanzeige

Seitenaufrufe

7
Letzte Woche
0
Letzter Monat
0
geprüft am 18.05.2024

Google ScholarTM

Prüfen

Altmetric